Ignite Creation Date:
2024-10-25 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06644521
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
Angiogenic Factors in the Placentas of Women With COVID-19
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Comparison of Angiogenic Factors in the Placentas of Parturient Women With COVID-19
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aim There have been few studies since the beginning of the pandemic researching the histopathologies and conducting molecular investigations of the placentas of SARS-CoV-2 positive pregnant women The aim of this study was to analyze the changes in the expression of angiogenic growth factors in the placentas of pregnant women infected with SARS-CoV-2 the COVID-19 group and to make comparisons with the placentas of non-infected pregnant women the control group
Methods Placentas taken at birth from 20 healthy women control and 20 women with a positive test for COVID-19 were prepared for histopathological examination Immunohistochemical staining was applied in placental tissues with ACE2 Angiotensin-conversion enzyme-2 VEGF Vascular Endothelial Growth Factor VEGFR-1 Vascular Endothelial Growth Factor Receptor 1 and PDGF Platelet-Derived Growth Factor
Results First the presence of COVID-19 in the placental tissue was assessed by the ACE2 immunohistochemical method It was seen that ACE2 was expressed weakly in the placental syncytiotrophoblast cells of non-infected women but in the syncytiotrophoblasts of the placentas of women infected with COVID-19 ACE2 expression was much higher VEGF in the endothelial and stromal cells of the villi of the control group was very strong but in the villi of infected placentas it was significantly weaker VEGFR-1 was positive in the endothelial membranes of the villi of the control group but was significantly weaker in the villi of infected placentas PDGF expression was strong in the syncytiotrophoblast and stromal cells of the control group but was significantly noticeably weaker in COVID-19 positive placentas
Methods Placentas taken at birth from 20 healthy women control and 20 women with a positive test for COVID-19 were prepared for histopathological examination Immunohistochemical staining was applied in placental tissues with ACE2 Angiotensin-conversion enzyme-2 VEGF Vascular Endothelial Growth Factor VEGFR-1 Vascular Endothelial Growth Factor Receptor 1 and PDGF Platelet-Derived Growth Factor
Results First the presence of COVID-19 in the placental tissue was assessed by the ACE2 immunohistochemical method It was seen that ACE2 was expressed weakly in the placental syncytiotrophoblast cells of non-infected women but in the syncytiotrophoblasts of the placentas of women infected with COVID-19 ACE2 expression was much higher VEGF in the endothelial and stromal cells of the villi of the control group was very strong but in the villi of infected placentas it was significantly weaker VEGFR-1 was positive in the endothelial membranes of the villi of the control group but was significantly weaker in the villi of infected placentas PDGF expression was strong in the syncytiotrophoblast and stromal cells of the control group but was significantly noticeably weaker in COVID-19 positive placentas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None